PALI ▲ +0.6% - Palisade Bio, Inc. $PALI - Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance Palisade Bio gained 0.6% after Health Canada cleared its clinical trial application for the Phase 2b ASCENTRA-UC program, expanding the company's ability to test its ulcerative colitis candidate in additional markets beyond its existing trial footprint. 23-SEP-2026 08:45 AM ET